Pharmacokinetics of cefuroxime in pregnant patients with preterm premature rupture of the membranes.
To 6 pregnant patients with preterm premature rupture of the membranes, cefuroxime prophylaxis was given 1,500 mg three times daily intravenously. Cefuroxime concentrations were assayed in maternal plasma and amniotic fluid during pregnancy and in umbilical cord blood, placenta, and membranes after delivery. Our results showed a high rate of transplacental transfer of cefuroxime. Bactericidal levels could be demonstrated in maternal plasma, and in amniotic fluid leaking from the vagina. Therapeutically active levels were present in the newborns. The absorption of cefuroxime by the foetal membranes was high. Although the neonatal morbidity in this high-risk population was low, the data are still too preliminary to advise the routine prophylactic use of cefuroxime to pregnant patients with preterm premature rupture of the membranes.
Roumen
F J
FJ
Department of Obstetrics and Gynaecology, St. Elisabeth Clinic, Heerlen, The Netherlands.
Bouckaert
P X
PX
Cremers
H M
HM
Vree
T B
TB
D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D002444:Cefuroxime / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005321:Extraembryonic Membranes / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005322:Premature Rupture of Fetal Membranes / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000378:metabolism*
D002444:Cefuroxime